Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Utah
Clinical trial register · United States · industry-sponsored

Clinical Trials in Utah, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Utah

13 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
Phase 1/2
181
Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah
2026-01-13
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals
Phase 1/2
123
California, Texas, Utah
2025-12-05
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 3
31
California, Colorado, Florida, Pennsylvania, Utah
2025-11-27
Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001Still´s Disease
Novartis Pharmaceuticals
Phase 2
30
Ohio, Oregon, Utah
2025-11-03
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Active, closed
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals
Phase 2
33
Oregon, Utah
2023-02-28
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
195
Florida, New York, Ohio, Pennsylvania, Utah
2023-02-10
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/utah

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Utah that also match the filters currently applied.

How many clinical trials are recruiting in Utah?

10 of the 13 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Utah), 13 studies
PhaseStudiesRecruitingShare
Phase 35438.5%
Phase 1/23323.1%
Phase 23223.1%
Phase 12115.4%

Most active sponsors

Lead sponsors with the most studies (Utah)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals1310
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.